No Reduction in Composite End Point for Bivalirudin in PCI

This article originally appeared here.
Share this content:
No Reduction in Composite End Point for Bivalirudin in PCI
No Reduction in Composite End Point for Bivalirudin in PCI

MONDAY, Aug. 28, 2017 (HealthDay News) -- Bivalirudin is not associated with a lower rate of the composite of any cause death, myocardial infarction, or major bleeding compared with heparin for patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction, according to a study published online Aug. 27 in the New England Journal of Medicine. The research was published to coincide with the European Society of Cardiology Congress 2017, held from Aug. 26 to 30 in Barcelona, Spain.

David Erlinge, M.D., Ph.D., from Lund University in Sweden, and colleagues enrolled patients with ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving a potent P2Y12 inhibitor to receive bivalirudin or heparin during PCI. A total of 6,006 patients were enrolled (3,005 with STEMI and 3,001 with NSTEMI).

The researchers found that a primary end point event (composite of death from any cause, myocardial infarction, or major bleeding during 180 days of follow-up) occurred in 12.3 and 12.8 percent of patients in the bivalirudin and heparin groups, respectively (hazard ratio, 0.96; 95 percent confidence interval, 0.83 to 1.10; P = 0.54). The results were consistent across those with STEMI and NSTEMI and other major subgroups.

"The rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and the Medicines Company, which funded the study.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Structural Findings of Acute Solar Retinopathy Described

Structural Findings of Acute Solar Retinopathy Described

Patient in case study presented three days after viewing solar eclipse

Telomere Fusions Predict Dysplasia, Invasive Pancreatic CA

Telomere Fusions Predict Dysplasia, Invasive Pancreatic CA

Telomere fusions are detected in later stages of intraductal papillary mucinous neoplasm progression

Prenatal Sugar Intake May Increase Asthma Risk in Offspring

Prenatal Sugar Intake May Increase Asthma Risk in ...

Higher intake during pregnancy, in early childhood associated with childhood asthma development

is free, fast, and customized just for you!

Already a member?

Sign In Now »